Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GAPDH | P04406 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.35 |
| ▸ | RELA | Q04206 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413244 | 0.92 | LMNA (0.41) | CA2CA5AHSD17B10LMNAGAA | |
| SCHEMBL2181693 | 0.89 | CA2 (0.41) | CA2CA5AHSD17B10LMNAGAA | |
| SCHEMBL2180009 | 0.83 | CA2 (0.44) | CA2CA5AHSD17B10LMNAGAA | |
| SCHEMBL2182312 | 0.83 | CA2 (0.44) | CA2CA5AHSD17B10LMNAGAA | |
| SCHEMBL13970428 | 0.81 | CA2 (0.43) | CA2CA5AHSD17B10LMNAGAA | |
| SCHEMBL12413254 | 0.81 | LMNA (0.42) | CA2CA5AHSD17B10LMNAGAA | |
| SCHEMBL2181652 | 0.81 | CA2 (0.42) | CA2CA5AHSD17B10LMNAGAA | |
| SCHEMBL12503502 | 0.80 | CA2 (0.35) | CA2CA5AHSD17B10LMNAGAA | |
| SCHEMBL2183407 | 0.80 | CA2 (0.41) | CA2CA5AHSD17B10LMNAGAA | |
| SCHEMBL2181747 | 0.80 | CA2 (0.44) | CA2CA5AHSD17B10LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| EP-2160385-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | Novogen Research Pty. Ltd. (AU) | 2010-03-10 | — | — | EP | disclosed |
| WO-2009003229-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LTD (AU) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NFE2L2, PTGS2, PTGES2 | CA2 1772/4885CA5A 2616/4885HSD17B10 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.